Browse U.S. drug recall enforcement reports from the FDA in a structured, searchable format. Review the recalled product, reason, firm, status, dates, distribution information and FDA classification when available.
10,685 detailed records are currently available in this category.
Labeling: Incorrect expiration date. Product dated with 24-month expiration date instead of 18-months.
Labeling: Incorrect expiration date. Product dated with 24-month expiration date instead of 18-months.
Labeling: Incorrect expiration date. Product dated with 24-month expiration date instead of 18-months.
Labeling: Incorrect expiration date. Product dated with 24-month expiration date instead of 18-months.
Subpotent Drug: FDA analysis found these products to be less than the labeled claim for the levothyroxine (T4) portion of the product.
Out-of-specification organic impurity results obtained during routine stability testing.
Labeling: Incorrect expiration date. Product dated with 24-month expiration date instead of 18-months.
CGMP Deviations: hand sanitizers were recalled because they were manufactured in the same facility as another hand sanitizer product with sub-potent ethanol levels.
CGMP Deviations: hand sanitizers were recalled because they were manufactured in the same facility as another hand sanitizer product with sub-potent ethanol levels.
Labeling: Incorrect expiration date. Product dated with 24-month expiration date instead of 18-months.
Sub-Potent Drug; Killz GERMz was recalled due to sub-potent results. Testing revealed ethanol levels as low as 62% while labelled claim is 70%.
Sub-Potent Drug; Killz GERMz was recalled due to sub-potent results. Testing revealed ethanol levels as low as 62% while labelled claim is 70%.
Subpotent Drug: Product testing identified a decreased level of the active ingredient, Cysteamine HCl.
Labeling: Not Elsewhere Classified. Container packaging is made, formed or filled to be misleading, resembling food and drink pouches
cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level per manufacturer
cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot
cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
CGMP deviations; repackaged product was recalled by the manufacturer because it was manufactured under the same conditions as products found to be sub-potent.
Failed Stability Specifications: Below specification result for buprenorphine release rate.
CGMP Deviations: recalled because it was manufactured in the same facility as the product found to contain methanol which represents poor Current Good Manufacturing Practices.
CGMP Deviations: Detection of N-nitrosodimethylamine (NDMA) impurity in finished drug product.
CGMP Deviations: recalled because it was manufactured in the same facility as the product found to contain methanol which represents poor Current Good Manufacturing Practices.
A drug recall record can include the reason for recall, firm, status, distribution pattern, quantity and FDA classification. This site does not provide medical advice; it organizes public recall information and links users back to official sources.
Recall Lookup USA keeps the last complete source record available when an official data service is temporarily unavailable. When a source provides only a few fields, we show only those known facts rather than padding the page with generic text.
This database is designed for discovery and reference. It can help you locate a relevant recall record, identify the recalling firm or NHTSA campaign, compare dates and classifications, and follow the official source. It is not a substitute for a VIN-specific NHTSA check, a manufacturer notice, medical advice or instructions issued by the recalling company.
